Medicare has taken a significant step in reducing the cost of prescription drugs by negotiating prices for the first time. This move targets 10 popular medications, aiming to save $6 billion in the first year alone.
The price cuts are part of the Inflation Reduction Act, designed to lower healthcare costs for millions of seniors. For example, the price of Eliquis, a blood thinner, is expected to drop by up to 60%, the diabetes drug Jardiance will see similar reductions, and the cholesterol-lowering drug Repatha may decrease by up to 50%. By enabling direct negotiations with drug manufacturers, Medicare aims to curb the rapid rise in drug prices, easing the financial burden on many Americans.
These actions are expected to significantly reduce out-of-pocket expenses, providing much-needed relief to those struggling with high medication costs. When the discounts take effect in 2026, the lower prices could result in $6 billion in net savings for Medicare in the first year alone.”